Search

Your search keyword '"Kritharides, L"' showing total 1,133 results
Start Over Author "Kritharides, L"
1,133 results on '"Kritharides, L"'

18. Increased Access to Percutaneous Coronary Intervention in Metropolitan and Regional Hospitals and Associated Marked Reduction in Long-term Mortality Post ST-elevation Myocardial Infarction: A 20-year Australian Statewide Cohort Study

Author

Rubenis, I., primary, Yan, A., additional, Ne, J., additional, Virk, S., additional, Yong, A., additional, Roy, P., additional, Lowe, H., additional, Kritharides, L., additional, Brieger, D., additional, and Ng, A., additional

Published
2023
Full Text
View/download PDF

40. Predictors of Major Adverse Cardiovascular Events: First Report From the Australian-New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry

Author

Dang, Q., Psaltis, P., Burgess, S., Chandrasekhar, J., Mukherjee, S., Kritharides, L., Jepson, N., Fairley, S., Ihdayhid, A., Layland, J., Szirt, R., El-Jack, S., Puri, A., Davis, E., Shiekh, I., Arnold, R., Watts, M., Marathe, J., Bhagwandeen, R., Wing-Lun, E., Bhindi, R., Ford, T., Lo, S., Marschner, S., and Zaman, S.

Published
2024
Full Text
View/download PDF

46. Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.

Author

West, M, Kirby, A, Stewart, RA, Blankenberg, S, Sullivan, D, White, HD, Hunt, D, Marschner, I, Janus, E, Kritharides, L, Watts, GF, Simes, J, Tonkin, AM, LIPID Study Group *, West, M, Kirby, A, Stewart, RA, Blankenberg, S, Sullivan, D, White, HD, Hunt, D, Marschner, I, Janus, E, Kritharides, L, Watts, GF, Simes, J, Tonkin, AM, and LIPID Study Group *

Abstract

Background Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long-term or is independent of renal function and other important biomarkers. Methods and Results Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow-up, 6 years) and long-term (median follow-up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR-creatinine, then GFR-creatinine-cystatin C). Over 6 years, in fully adjusted multivariable time-to-event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07-1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19-1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all-cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR-creatinine-cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28-10.20) independently of estimated GFR-creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR-creatinine-cystatin C. Conclusions Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all-cause mortality. Prediction of long-term mortality was independent of improved estimation of GFR. Registration URL: https://anzctr.org.au; Unique identifier: A

Published
2022

47. B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease.

Author

Stewart, RAH, Kirby, A, White, HD, Marschner, SL, West, M, Thompson, PL, Sullivan, D, Janus, E, Hunt, D, Kritharides, L, Keech, A, Simes, J, Tonkin, AM, Stewart, RAH, Kirby, A, White, HD, Marschner, SL, West, M, Thompson, PL, Sullivan, D, Janus, E, Hunt, D, Kritharides, L, Keech, A, Simes, J, and Tonkin, AM

Abstract

Background The plasma concentration of B-type natriuretic peptide (BNP) is a strong predictor of adverse cardiovascular events. The aim of this study was to determine whether the association between plasma BNP concentration and cardiovascular mortality is sustained or diminishes with increasing time after BNP is measured. Methods and Results Six thousand seven hundred forty patients with a history of myocardial infarction or unstable angina who participated in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) trial had plasma BNP concentration measured at baseline and after 1 year. Associations with cardiovascular mortality were evaluated in landmark analyses 1 to <5, 5 to <10, and 10 to 16 years after randomization. There were 1640 cardiovascular deaths. The cardiovascular mortality rate increased progressively from 10.2 to 19.1 to 26.3/1000 patient-years from 1 to <5, 5 to <10, and 10 to 16 years after baseline, respectively. The average of baseline and 1-year BNP concentration was more strongly associated with cardiovascular mortality compared with baseline or 1-year BNP only. The hazard ratio (HR) for cardiovascular death associated with each doubling of average BNP concentration was similar during years 1 to <5 (HR, 1.53 [95% CI, 1.44-1.63]), years 5 to <10 (HR, 1.52 [95% CI, 1.44-1.60]), and years 10-16 (HR, 1.43 [95% CI, 1.36-1.50]), P<0.0001 for all. Conclusions BNP concentration remains an independent predictor of cardiovascular mortality more than a decade after it is measured. Because of random variation in plasma concentrations, the average of >1 BNP measurement improves long-term risk prediction.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results